Citi Pharma Partners With Mersi Farma to Boost API Manufacturing, Nutraceutical Market in Indonesia

Citi Pharma Limited and Mersi Farma (Indonesia Based Leading Pharmaceutical Company) have forged a strategic partnership to advance API manufacturing and expand the Nutraceutical Market in Indonesia.

Citi Pharma Limited is proud to announce the signing of a Memorandum of Understanding (MOU) with Mersi Farma, marking a transformative collaboration to establish Active Pharmaceutical Ingredient (API) manufacturing facilities and expand nutraceutical product accessibility in Indonesia.

Key Provisions of the Partnership:

1. Development of Advanced API Manufacturing Facilities

Paracetamol API Plant: A state-of-the-art facility with an annual production capacity of 10,000 metric tons per
annum.

Amoxicillin API Plant: A high-capacity plant with an annual production capacity of 1,800 metric tons per annum.

These facilities will meet Pharmaceutical Inspection Co-operation Scheme (PIC/S) compliance standards, ensuring the highest quality production processes. The Paracetamol and Amoxicillin plants will be the first large-scale API manufacturing facilities in Indonesia, significantly reducing the country’s dependence on imported APIs.

This strategic initiative aims to bolster local production capacity, enhance self-reliance, and contribute to Indonesia’s healthcare infrastructure.

2. Joint Investment and Expertise Deployment

Citi Pharma Limited will provide substantial capital investment and integrate state-of-the-art technology to establish world-class production capabilities.

Mersi Farma will co-invest and utilize its extensive operational network within Indonesia to oversee operations and optimize market distribution for APIs.

3. Nutraceutical Market Penetration in Indonesia

Citi Pharma Limited will introduce its premium nutraceutical product range, catering to the growing demand for health and wellness solutions.

Mersi Farma will manage the marketing, sales, and distribution of these products through its robust and well-established local distribution framework.

Strategic Implications

This partnership is a cornerstone of shared efforts to:

• Drive innovation in the pharmaceutical and nutraceutical sectors.
• Enhance regional healthcare accessibility through localized and high-quality API manufacturing.
• Promote economic sustainability by reducing Indonesia’s reliance on API imports and fostering local industrial growth.

With the first bulk API manufacturing plant in Indonesia, this collaboration represents a pivotal shift toward self-sufficiency and technological advancement in the country’s healthcare landscape.